GLP-1 Pills - Search News

FDA to halt compounded versions of GLP-1 drugs

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

ABC News · 22h

Compound versions of some weight loss drugs to be restricted

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.

BBC · 1d

Who can get weight loss drugs on the NHS in Scotland?

The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,

AOL · 1d

Compound versions of weight loss drugs will no longer be available, FDA rules

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.

VideoElephant (Video) on MSN · 1d

Medications For Weight Loss

Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.

News-Medical.Net on MSN3d

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

MedPage Today on MSN7d

Use of GLP-1 Drugs for Obesity Linked to Lower Risk of Glaucoma

The findings were in line with those of a large retrospective cohort study that showed that patients treated with GLP-1 ...

Endocrinology Advisor1d

GLP-1 Drugs Associated With a Reduced Risk of Multiple Age-Related Ocular Diseases

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

ConsumerAffairs8d

GLP-1 insurance coverage worsened at start of 2025, report says

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

6don MSN

Novo Nordisk to explore how GLP-1 drugs can help patients with addiction

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

GLP-1 Drugs Improve Outlook For Kidney Transplants

Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need ...

23h

PatchMD Introduces New GLP-1 Support Patches for Individuals on Weight Loss Medications

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

12d

This Could Be the Best GLP-1 Stock to Buy in 2025

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

13don MSN

GLP-1 diabetes drugs not linked to heightened suicidality risk

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results